Literature DB >> 27374118

A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis.

Haruya Kawase1, Yasuko K Bando2, Kazuyuki Nishimura1, Morihiko Aoyama1, Akio Monji1, Toyoaki Murohara3.   

Abstract

BACKGROUND: To address the impact of antidiabetic drugs on cardiovascular safety is a matter of clinical concern. Preclinical studies revealed that various protective effects of dipeptidyl peptidase-4 inhibitor (DPP4i) on cardiovascular disease; however, its impact of on hypertension remains controversial. METHODS AND
RESULTS: Teneligliptin (TEN; 10mg/kg/day/p.o.) ameliorates hypertension and cardiac remodeling by normalizing a rise of angiotensin-II (AngII) that specifically observed in spontaneously hypertensive rats (SHR). TEN had no effects on vasculature and concentrations of the DPP4-related vasoactive peptides (bradykinin, neuropeptide Y, and atrial natriuretic peptide). The primary action of TEN on BP lowering was due to restoring the AngII-induced manifestation of congestive heart failure observed in SHR. Sodium-proton pump exchanger type 1 (NHE-1) is a regulator of intracellular acidity (pHi) and implicated pathophysiological role in cardiac remodeling occurred in diseased myocardium. Cardiac NHE-1 expression level was increased in SHR and this was restored in TEN-treated SHR. AngII directly augmented cardiac NHE-1 expression and its activity that contributed to hypertrophic response. TEN attenuated the AngII-induced cardiac hypertrophy with decline in pHi via suppression of NHE-1. Loss of NHE-1 activity by specific inhibitor or RNA silencing promoted intracellular acidification and consistently attenuated the AngII-mediated cardiac hypertrophy.
CONCLUSION: The present study revealed the protective actions of TEN on hypertension and comorbid cardiac remodeling via AngII/NHE-1 axis and the novel pathophysiological roles of intracellular acidification via NHE-1 in cardiac hypertrophy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiotensin-II; Cardiac remodeling; Dipeptidyl peptidase-4 inhibitor; Hypertension; Sodium-proton pump exchanger

Mesh:

Substances:

Year:  2016        PMID: 27374118     DOI: 10.1016/j.yjmcc.2016.06.066

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  Reduced Nhe1 (Na+-H+ Exchanger-1) Function Protects ApoE-Deficient Mice From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysms.

Authors:  Cong-Lin Liu; Xin Liu; Yunzhe Wang; Zhiyong Deng; Tianxiao Liu; Galina K Sukhova; Gregory R Wojtkiewicz; Rui Tang; Jin-Ying Zhang; Samuel Achilefu; Matthias Nahrendorf; Peter Libby; Xiaofang Wang; Guo-Ping Shi
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction.

Authors:  Jing-Wei Li; Yun-Dai Chen; Wei-Ren Chen; Qi You; Bo Li; Hao Zhou; Ying Zhang; Tian-Wen Han
Journal:  Cardiovasc Diabetol       Date:  2017-06-06       Impact factor: 9.951

Review 3.  The regulatory role of DPP4 in atherosclerotic disease.

Authors:  Lihua Duan; Xiaoquan Rao; Chang Xia; Sanjay Rajagopalan; Jixin Zhong
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

4.  Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial.

Authors:  Koh Ono; Hiromichi Wada; Noriko Satoh-Asahara; Hitoki Inoue; Keita Uehara; Junichi Funada; Atsushi Ogo; Takahiro Horie; Masatoshi Fujita; Akira Shimatsu; Koji Hasegawa
Journal:  Am J Cardiovasc Drugs       Date:  2020-06       Impact factor: 3.571

Review 5.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

6.  Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.

Authors:  Maria Mirabelli; Eusebio Chiefari; Luigi Puccio; Daniela Patrizia Foti; Antonio Brunetti
Journal:  Int J Environ Res Public Health       Date:  2020-05-22       Impact factor: 3.390

7.  Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus.

Authors:  Liying Mu; Zhuo Wang; Jinmei Ren; Xiaowei Xiong; Zening Jin; Xin Liu
Journal:  Diabetol Metab Syndr       Date:  2022-02-14       Impact factor: 3.320

Review 8.  DPP4 as a Potential Candidate in Cardiovascular Disease.

Authors:  Si-Yu Chen; Xiang-Quan Kong; Ke-Fan Zhang; Shuai Luo; Feng Wang; Jun-Jie Zhang
Journal:  J Inflamm Res       Date:  2022-09-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.